©TheCanadian Journal ofUrology™: International Supplement, April 2014
36
Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into
clinical practice
7. Scher HI, Heller G. Clinical states in prostate cancer: toward
a dynamic model of disease progression.
Urology
2000;55(3):
323-327.
8. MurphyWM, SolowayMS, Barrows GH. Pathologic changes
associated with androgen deprivation therapy for prostate
cancer.
Cancer
1991;68(4):821-828.
9. CivantosF,MarcialMA,BanksERetal.Pathologyofandrogen
deprivation therapy inprostatecarcinoma.Acomparativestudy
of 173patients.
Cancer
1995;75(7):1634-1641.
10.DjavanB, Eastham J, GomellaLet al. Testosterone inprostate
cancer: theBethesda consensus.
BJU Int
2012;110(3):344-352.
11.PagliaruloV, BracardaS, EisenbergerMAet al.Contemporary
role of androgen deprivation therapy for prostate cancer.
EurUrol
2012;61(1):11-25
12.TsaiHT, PensonDF,Makambi KH, Lynch JH, VanDenEeden
SK, PotoskyAL. Efficacyof intermittent androgendeprivation
therapy vs conventional continuous androgen deprivation
therapy foradvancedprostatecancer: ameta-analysis.
Urology
2013;82(2):327-334.
13.Niraula S, Le LW, Tannock IF. Treatment of prostate cancer
with intermittent versus continuous androgen deprivation: a
systematicreviewofrandomized trials.
JClinOncol
2013;31(16):
2029-2036.
14.Mohler JL, ArmstrongAJ, Bahnson RR et al. Prostate cancer,
version3.2012: featuredupdates to theNCCNguidelines.
JNatl
ComprCancNetw
2012;10(9):1081-1087.
15.AllardCB,DasonS,LusisJ,KapoorA.Prostatecancerscreening:
Attitudes and practices of family physicians in Ontario.
Can
UrolAssoc J
2012;6(3):188-193.
16.StuderUE,WhelanP,WimpissingerFet al.Differences in time to
disease progressiondo not predict for cancer-specific survival in
patients receiving immediate or deferred androgen-deprivation
therapy forprostate cancer: final resultsof eortc randomized trial
30891with12yearsoffollow-up.
EurUrol
2013.Epubaheadofprint.
17.BlackardCE,ByarDP, JordanWP, Jr.Orchiectomy foradvanced
prostaticcarcinoma.Areevaluation.
Urology
1973;1(6):553-560.
18. Immediate versus deferred treatment for advanced prostatic
cancer: initial results of the Medical Research Council Trial.
TheMedical ResearchCouncil ProstateCancerWorkingParty
InvestigatorsGroup.
Br JUrol
1997;79(2):235-246.
19.Walsh PC, DeWeese TL, Eisenberger MA. A structured
debate: immediate versus deferred androgen suppression in
prostate cancer-evidence for deferred treatment.
J Urol
2001;
166(2):508-515;discussion515-516.
20.Silva FC, Silva FM, Goncalves F et al. Locally advanced and
metastatic prostate cancer treatedwith intermittent androgen
monotherapy or maximal androgen blockade: results from a
randomisedphase3studyby theSouthEuropeanUroncological
Group.
EurUrol
2013. Epub aheadof print.
21.Crook JM, O’Callaghan CJ, Duncan G et al. Intermittent
androgen suppression for risingPSA level after radiotherapy.
NEngl JMed
2012;367(10):895-903.
22.HussainM, Tangen CM, Berry DL et al. Intermittent versus
continuous androgendeprivation in prostate cancer.
NEngl J
Med
2013;368(14):1314-1325.
23.Langenhuijsen J, Schasfoort E, Heathcote P et al. Intermittent
androgen suppression in patients with advanced prostate
cancer:anupdateoftheTULPsurvivaldata.
EurUrolSuppl
2008;
7(3):205.
24.De Leval J, Boca P, Youssef E et al. Intermittent versus
continuous totalandrogenblockade in the treatmentofpatients
with advanced hormone-naive prostate cancer: results of a
prospective randomizedmulticenter trial.
ClinProstate Cancer
2002;1(3):163-171.
25.Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S,
Tammela TL. The FinnProstate StudyVII: intermittent versus
continuous androgen deprivation in patients with advanced
prostate cancer.
JUrol
2012;187(6):2074-2081.
26.Mottet N, VanDamme J, Loulidi S, Russel C, LeitenbergerA,
Wolff JM. Intermittent hormonal therapy in the treatment of
metastatic prostate cancer: a randomized trial.
BJU Int
2012;
110(9):1262-1269.
27.KlotzL. Intermittent versus continuous androgendeprivation
therapy inadvancedprostate cancer.
CurrUrol Rep
2013;14(3):
159-167.
28.Dason S, Allard CB, Tong J, Shayegan B. Defining a new
testosterone threshold for medical castration: results from a
prospectivecohortseries.
CanUrolAssocJ
2013;7(5-6):E263-E267.
29.Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S,
TammelaTL.Advancedprostatecancertreatedwith intermittent
or continuous androgen deprivation in the randomised
FinnProstateStudyVII:qualityoflifeandadverseeffects.
EurUrol
2013;63(1):111-120.
30.Strum SB, McDermed JE, ScholzMC, Johnson H, Tisman G.
Anaemia associated with androgen deprivation in patients
with prostate cancer receiving combined hormone blockade.
Br JUrol
1997;79(6):933-941.
31.Malcolm JB, Derweesh IH, Kincade MC et al. Osteoporosis
and fracturesafterandrogendeprivation initiation forprostate
cancer.
Can JUrol
2007;14(3):3551-3559.
32.Yu EY, Kuo KF, Gulati R et al. Long-term dynamics of bone
mineral densityduring intermittent androgendeprivation for
men with nonmetastatic, hormone-sensitive prostate cancer.
JClinOncol
2012;30(15):1864-1870.
33.AlibhaiSM,RahmanS,WardePR, JewettMA, JafferT,Cheung
AM. Prevention and management of osteoporosis in men
receivingandrogendeprivation therapy: asurveyofurologists
and radiationoncologists.
Urology
2006;68(1):126-131.
34.Nguyen PL, Je Y, Schutz FA et al. Association of androgen
deprivation therapywithcardiovasculardeath inpatientswith
prostate cancer: a meta-analysis of randomized trials.
JAMA
2011;306(21):2359-2366.
35.Tombal B, Albertsen P, De La TailleA et al. 677 Lower risk of
cardiovascular (CV)eventsanddeath inmenreceivingADTby
gonadotropinreleasinghormone (GnRH)antagonist,degarelix,
comparedwith luteinisinghormone-releasing(LHRH)agonists.
EurUrol Suppl
2013;12(1):e677-e678.
36.Lapi F, Azoulay L, Niaz Lapi F et al. Androgen deprivation
therapyandriskofacutekidney injury inpatientswithprostate
cancer.
JAMA
2013;310(3):289-296.
37.GrossmannM,Zajac JD.Androgendeprivation therapy inmen
withprostatecancer: howshould thesideeffectsbemonitored
and treated?
ClinEndocrinol
2011;74(3):289-293.
